Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of intramuscular injection of xiyanping injection in the treatment of acute bronchitis in children

Conditions: Acute Bronchitis in Children

Summary: any pathogen that causes an upper respiratory tract infection can cause bronchitis.the primary pathogen is virus. on the basis of virus infection, pathogenic bacteria may cause secondary infection or co-infection。xiyanping injection is mainly used in the treatment of bronchitis by intravenous injection。

to further verify the clinical value and safety of intramuscular injection of xiyanping injection in the treatment of acute bronchitis in children, provide reference for subsequent validation studies, and provide more reasonable and standard application guidance and basis for clinical practice.a multicenter, randomized, parallel controlled study was conducted on the treatment of acute bronchitis by intramuscular injection of xiyanping injection.

Eligibility criteria:
inclusion criteria: 1. age: 1-6 years (\>1 years, ≤6years); 2. children who meet the diagnosis criteria of acute bronchitis in children; 3. all symptoms, including cough, had been present for less than 72 hours at the time of inclusion screening; 4. the informed consent process complies with the regulations, and the legal guardian signs the informed consent. exclusion criteria: 1. have used chinese medicine injection containing andrographolide and similar functions (clearing heat and detoxifying, relieving cough and stopping dysentery) or oral dosage within 72 hours. 2. children with severe bronchitis or early pneumonia; 3. children with acute infectious diseases such as measles, pertussis,influenza and hand-foot-and-mouth disease; 4. children with diseases such as acute upper respiratory tract infection, suppurative tonsillitis, wheezing bronchitis, bronchial asthma, bronchiolitis pneumonia, tuberculosis, tumor; 5. neutrophil granulocyte\>80%, or those who need antibiotic therapy; 6. children with severe malnutrition and immunodeficiency; 7. children with severe primary diseases such as heart, liver, kidney, digestion and hematopoietic system; 8. allergic constitution and children allergic to the drug used in this study; 9. children who are taking epinephrine, isoproterenol and other catecholamines; 10. children who are taking mao inhibitors or tricyclic antidepressants 11. children who are taking non-selective β-blockers such as propranolol; 12. those who are not included based on the investigators judgment.
covering of the abdominal wall in laparotomies: differences in surgical site infections between an approved abdominal 3m™ steri-drape™ wound edge protector and standard woven swabs at technische universität münchen

Conditions: Comparing the Number of Surgical Site Infections; Covering of the Abdominal Wall in Laparotomies With an Approved Abdominal 3M™ Steri-Drape™ Wound Edge Protector and Standard Woven; Swabs

Summary: bafo is a prospective, double-blinded randomized controlled clinical trial that assesses the numbers of surgical site infections in two different techniques of covering the abdominal wall in laparotomies. standard covering with woven swabs is compared to a novel, approved 3m™ steri-drape™ wound edge protector.


Eligibility criteria:
inclusion criteria: * ability to sign the informed consent * patients older than 18 years * abdominal operations with longitudinal / cross section with clean wounds, clean-contaminated wounds or contaminated wounds (cdc-definitions of surgical wound infections) exclusion criteria: * pregnant or lactating women * revision operations * operations with dirty or infected wounds (cdc definition of surgical wound infections) * laparoscopic operations * small operations without longitudinal- / cross-section e.g. appendectomy

Keywords: surgical site infections covering the abdominal wound edge in laparotomies
nasal steam therapy for post-extubation respiratory events

Conditions: Thyroid Cancer; Intubation

Summary: the effect of symptom improvement of nasal steam strategy compared to routine management strategy for upper respiratory symptoms occurring after endotracheal intubation in patients aged 19 years or older who underwent surgical removal under anesthesia requiring endotracheal intubation was evaluated by the difference in the results of wisconsin upper respiratory symptom survey

this study aims to confirm the comparative effectiveness of nasal steam therapy by conducting a practical randomized controlled clinical trial comparing 66 patients complaining of upper respiratory symptoms with patients treated with a nasal steam therapy strategy (33 patients) and patients treated with a routine management strategy (33 patients). this study is a practical clinical study, and only randomly assigns patients to two groups: nasal steam therapy strategy and routine management strategy. the specific treatment method used is not determined in advance. the specific treatment is performed according to the clinical judgment according to the patient's condition. all treatment methods used during the study are recorded in the case report and compared. the treatment will be administered for a total of 5 days, and drug treatment may not be discontinued after the study period at the clinician's discretion.

Eligibility criteria:
inclusion criteria: * age of 19 to 69 years * those who underwent surgical removal of the thyroid gland under endotracheal intubation due to a thyroid tumor * american society of anesthesiologists (asa) status i or ii * those who developed upper respiratory symptoms after surgery ⑤ voluntarily decided to participate in this clinical trial and signed the informed consent form exclusion criteria: * those diagnosed with symptomatic gastroesophageal reflux disease * chronic cough lasting for more than 3 months prior to surgery, including bronchial asthma and chronic obstructive pulmonary disease (copd) * those who developed other respiratory infections within the past month ④ those who are taking or are required to take other medications that may interfere with the interpretation of the treatment effect or results * those who are scheduled to undergo additional major treatments such as reoperation, chemotherapy, and radiotherapy during the clinical trial period ⑥ pregnant women, breastfeeding women, and those who plan to become pregnant during the study period ⑦ others who are expected to have difficulty complying with the treatment, visits, and questionnaires stipulated in this protocol at the discretion of the medical staff

Keywords: thyroid cancer post-extubaton upper respiratory event
autologous natural killer cell therapy for hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: this study represents a phase i clinical trial that utilizes natural killer (nk) cell therapy for patients diagnosed with liver cancer, specifically those classified as child-pugh a and falling within the barcelona clinic liver cancer (bclc) stages b or c. the expected results include determining the suitable treatment dosage, identifying any resulting side effects, and calculating the average duration of progression-free survival. the target group for the study consists of all individuals diagnosed with liver cancer. at the same time, the practical sample consists of those who received medical care for liver cancer at cipto mangunkusumo hospital (rscm) between may and december 2022. the chosen research sample comprises liver cancer patients who fulfill the predetermined participation criteria. the necessary sample size for discerning appropriate treatment dosages and the occurrence rate of potential side effects shall consist of 2-3 liver cancer patients who are administered autologous nk cells. the process for isolating these nk cells adheres to the guidelines established by miltenyi biotec.


Eligibility criteria:
inclusion criteria: * patients aged 20-60 years old * patients with hepatocellular carcinoma (hcc) staged as bclc b and c * karnofsky performance status (kps) score ≥ 70 * expected patient survival of more than three months * the following parameters are within the normal range: platelet count ≥ 80,000/µl white blood cell count ≥ 3000/µl neutrophil count ≥ 2000 hemoglobin ≥ 9 mg/dl international normalized ratio (inr) 0.8-1.5 adequate liver function (bilirubin \< 2, sgot and sgpt \< 60 u/l) adequate kidney function (serum creatinine \< 1.3, serum urea \< 10) exclusion criteria: * refusing to participate in the study * afflicted by other malignancies, whether non-hcc liver or other malignancies * patients are affected by other conditions such as hypertension, severe coronary disease, myelosuppression, respiratory disorders, and acute or chronic infections * patients who have previously undergone transplantation and received other stem cell therapies

Keywords: natural killer cell immunotherapy hepatocellular carcinoma
kangaroo holding effects on breast milk

Conditions: Premature Birth

Summary: kangaroo holding is a skin-to-skin method of holding a baby. many research studies have investigated the maternal and infant benefits associated with kangaroo holding. the purpose of this study is to determine if kangaroo holding a baby changes the amount and composition of breast milk pumped before and after the kangaroo holding session. hypotheses: 1. there is a significant difference in volume of maternal breast milk pumped after kangaroo holding premature infants as compared to maternal breast milk pumped after non-holding conditions 2. there is a significant difference in the composition of maternal breast milk pumped after kangaroo holding premature infants as compared to maternal breast milk pumped after non-holding condition.

this study will address two of the overwhelming challenges in the physiologic care of premature infants in the neonatal intensive care unit (nicu) environment. the first challenge is promoting neonatal growth through providing a careful balance of nutrition to caloric expenditure for premature infants. the second challenge is supporting parents in the intensive, technology driven environment of the nicu to merge physiologic care with parental-infant interaction through touch, communication, and maternal intervention. the vast majority of mothers with premature infants express breast milk for early feedings, however milk production tends to diminish three to four weeks after delivery. the practice of skin-to-skin holding is thought to promote the mother's ability to produce breast milk, but had not been empirically tested. this study will examine the relationship of kangaroo holding on mother's breast milk production and composition.

Eligibility criteria:
inclusion criteria: * birth weight \</= 2000 grams * gestational age 26-34 weeks at birth * medically stable at start of study * \< 14 days old at start of study exclusion criteria: * infants receiving phototherapy * suspected congenital abnormalities * overwhelming sepsis * cardiac abnormalities * suspected infections

Keywords: premature birth pumping breast milk kangaroo holding
comparison of different physiotherapy techniques in dysmenorrhea

Conditions: Dysmenorrhea Primary

Summary: this study is investigating the effects of myofascial release technique \& kinesiotape in managing dysmenorrhea

dysmenorrhea is a common gynecological disorder characterized by painful menstruation manifested by severe cramps in the lower abdomen. according to the world health organization (who) data, it affects 50-90% of women globally (10-20% of cases have severe symptoms); recent epidemiological studies in türkiye show that this rate is significantly high (75-85%).dysmenorrhea is divided into two types: primary dysmenorrhea (pd) and secondary dysmenorrhea. pd is painful menstruation without any underlying pathological condition. the main goal of dysmenorrhea treatment is to significantly improve the patient's well-being and quality of life (qol) by effectively relieving pain and relieving symptoms by targeting physiological mechanisms. there are various physiotherapy methods that can be used to reduce this pain, such as transcutaneous electrical nerve stimulation (tens), cryotherapy, myofascial release therapy (mrt), and kinesiology taping (kt). this single-blind randomized controlled trial will investigate the acute therapeutic effects of myofascial release technique (mrt) versus kinesio taping (kt) in 46 females aged 18-30 years with pd. participants will be randomised into group 1 (mrt; n = 23) or group 2 (kt; n = 23), receiving a single intervention session during their most painful menstrual day all participants will be asked to fill out 3 forms, namely a sociodemographic questionnaire covering age, height, bmi, age at menarche and duration of menstruation, a visual analog scale (vas) to assess pain level and a patient reported outcomes measurement system (promis-29 profile v2.0) to measure quality of life (qol) at 3 time points (pre-intervention, 8 hours after intervention ,and 3-5 weeks post intervention (at the first menstrual cycle after intervention). statistical analyses will be conducted by using spss 27.0 (ibm corp.), with a priori power analysis confirming 95% power (α = 0.05; g\*power v3.1.9.7). data normality will be verified via the shapiro-wilk test. independent samples t-tests will compare interventional effects between groups, while one-way anova (with lsd post-hoc tests) will analyze multi-point qol changes. paired samples t-tests will evaluate within-group temporal changes (pre vs. post-intervention).

Eligibility criteria:
inclusion criteria: diagnosis of primary dysmenorrhea, moderate-to-severe pain during menstrual days 1-3, regular menstrual cycles for past 6 months exclusion criteria: secondary gynaecological conditions, current use of pain medications, history of pregnancy

Keywords: primary dysmenorrhea kinesiotape myofascial release pain
factors associated with clinical outcomes in patients hospitalized for covid-19 in ght-93 est

Conditions: COVID; SARS-CoV 2

Summary: healthcare centers treated several hundreds of patients with covid-19 and prospectively gathered information in electronic format between march, 2020 to april, 2020. in the course of covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive). this cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for covid-19, by analyzing associations between treatments and outcomes. all data are collected in electronical records during routine practice.

healthcare centers treated several hundreds of patients with covid-19 and prospectively gathered information in electronic format between march, 2020 to april, 2020. in the course of covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive). this cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for covid-19. risk factors which will be studied include: baseline characteristics such as medical history and drugs with corresponding administration protocols. main outcomes include all-cause mortality, need for mechanical ventilation, for icu transfer and all relevant biological syndromes. all data are collected in electronical records during routine practice and additional data may be collected retrospectively.

Eligibility criteria:
inclusion criteria: * hospitalized for covid-19 * severe pneumonia defined as pulse o2 \ 6l/min exclusion criteria: * lack of consent * palliative care patients * patients in icu * patients transferred from icu

Keywords: covid-19 sars-cov-2
aidi - research & development of a multisensor-based machine learning technology for real-time automated detection of covid-19 decompensation

Conditions: Sars-CoV-2 Infection

Summary: the aidi study has to phases. it's purpose is to capture vital signs using a non-invasive, hand-held, home monitoring device (mouthlab device) from individuals with covid-19 or who test positive for sars-cov-2 (phase i) and use an algorithm-based approach to identify individuals at risk of clinical decompensation (phase ii). up to 500 unvaccinated and partially vaccinated subjects will be included (up to 100 in phase i and up to 400 in phase ii).


Eligibility criteria:
inclusion criteria: * male or female 18 years of age or older * unvaccinated individuals, or individuals who have received only 1 dose of an mrna vaccine * individuals who have received a positive sars-cov-2 result within 24-48 hours (lab-based pcr or antigen test) * willing and able to provide informed consent * ability to read, write, and comprehend english * have no functional limitation that would impede the use of the mouthlab device * willing to provide access to health information via electronic health records (ehr) exclusion criteria: * currently receiving hospice care * have a left ventricular assist device * left-sided hemiplegia or any other motor deficits that may restrict the use of the device. * individuals with cognitive deficits that impede their ability to comprehend and give informed consent. * individuals who are enrolled in any other investigational research studies of sars-cov2 or covid-19 * individuals who are treated with monoclonal antibody therapy prior to diagnosis * individuals who are admitted to a hospital or acute care facility at the time of diagnosis * individuals with pacemakers or implanted cardio-defibrillators (icds) * history of hemoptysis, pneumothorax, thoracic or abdominal aneurysm, pulmonary embolism, or stroke * history of unstable cardiovascular status, including recent myocardial infarction (mi within 30 days), unstable angina, or uncontrolled hypertension color blindness * chest, abdominal or eye surgery within the preceding 14 days * any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.
rosa® hip system tha pmcf

Conditions: Osteoarthritis, Hip; Avascular Necrosis of Hip

Summary: this study is a prospective, multicenter, single-arm, cohort post-market study to evaluate the accuracy of acetabular implant position using the robotic-arm surgical assistant (rosa® hip system).

consecutive patients who meet all of the inclusion criteria and none of the exclusion criteria will be eligible for participation in the study, and will be pre-screened for participation in the informed consent process. the primary objective of this study is to assess the accuracy of acetabular implant position by evaluating the percentage of participants who are within the range of the callanan safe zones for acetabular inclination (30 - 45 degrees). a patient is considered a success if their intra-operative and/or post-operative full pelvis fluoroscopic or radiographic images show the postoperative acetabular inclination to be within this safe zone range. secondary objectives include the evaluation of safety and efficacy of this system and will include the assessment of common adverse events, physical exam findings, radiologic results, and patient reported outcome measures. data collection will occur at the following intervals: pre-operative, operative, 3-months, 1-year, and 2-years. enrollment for the study is anticipated to last approximately 18 months. allowing for 24 months of follow-up, the total estimated study time to final-patient final-visit will be approximately 42 months.

Eligibility criteria:
inclusion: 1. age 18 - 80 years 2. body mass index ≤40 (bmi = kg/m2) 3. patient is willing and able to provide informed consent 4. patient qualifies for primary tha, via an anterior approach, due to osteoarthritis or avascular necrosis of the hip based on investigator's clinical judgment 5. independent of study participation, patient is a candidate and meets the indications and none of the contraindications for use with the rosa hip system exclusion: 1. has undergone an orthopaedic procedure of the spine or lower extremity, or is currently participating in a pain management clinical study of any joint, within the last 6 months or planned within the next 6 months 2. patients receiving simultaneous bilateral hip arthroplasties are excluded from participation in this study; as well as any participants with staged bilateral arthroplasties within 6 months of each other 3. active infection, sepsis, osteomyelitis 4. patient is at a high risk for dislocation including those with long-segment spinal fusions (\>3 levels) and neuromuscular disorders 5. inflammatory (rheumatoid or psoriatic arthritis) or post-traumatic arthropathy, or any other degenerative joint disease not consistent with osteoarthritis 6. would, in the investigator's opinion, be unwilling or unable to comply with the postoperative follow-up schedule 7. patient is considered a member of a vulnerable population (pregnant, prisoner, mentally incompetent, etc.) 8. previous hardware in the proximal femur or acetabulum from a prior orthopaedic procedure
can cox-2 inhibitor decrease stricture recurrence after direct vision internal urethrotomy?

Conditions: COX-2 Inhibitor; Meloxicam; Stricture Recurrence; Direct Vision Internal Urethrotomy

Summary: to evaluate the efficacy and safety of nonsteroidal anti-inflammatory drugs (nsaids) in preventing urethral stricture recurrence after direct visual internal urethrotomy.

the most common aetiology of urethral strictures is idiopathic, followed by iatrogenic causes, including transurethral resection, urethral catheterization, prostate cancer treatments, and previous hypospadias surgery. the recurrence rates are higher with previously treated, long and multiple strictures, penile compared with bulbar strictures, and those with perioperative infection. it has been reported that post-transurethral resection of the prostate (turp) to receive or not receive a cox-2 inhibitor (rofecoxib 25 mg/day) for 20 days. at 1 year of follow-up, a urethral stricture had been diagnosed in 17 and 0 % of cases without and with cox-2 treatment, respectively

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * american society of anesthesiologists (asa) score ≤3. * urethral stricture length ≤ 1.5 cm exclusion criteria: * recurrent urethral stricture ≥ 2 times. * pelvic fracture urethral distraction defect (pfudd).